





RE











BETH LEWIN DEAN
Chief Executive Officer of Citizens
United for Research in Epilepsy (CURE

...is an unknown. Some days, life can seem perfectly normal. Other days are filled with seizures and setbacks. Yet every day, our community faces this condition with courage as we continue to search for a cure.

At CURE, we're researching every day for those living with epilepsy. As the only nonprofit organization solely focused on epilepsy research, we've spent the last two decades seeking to understand the underlying causes of this condition, uncover promising therapies, and ultimately find a cure. The road is long, and we get closer with every day, every scientific breakthrough, and every gesture of support from our community.

In this issue of "Researching for a Cure," we share some of the most exciting discoveries that have filled our days over the past few months, including:

ASSEMBLING A TEAM OF 60+ COLLABORATORS AT INSTITUTIONS ACROSS THE GLOBE TO RESEARCH HOW TO PREDICT, TREAT, AND PREVENT POST-TRAUMATIC EPILEPSY


UNCOVERING ONE OF THE BIGGEST RISK FACTORS FOR SUDEP — AS WELL AS RECOMMENDATIONS TO REDUCE THOSE RISKS

DEEPENING OUR UNDERSTANDING OF EPILEPSIES CAUSED BY GRIN GENE MUTATIONS

You'll also hear inspiring stories from members of our community, including a young college student navigating school and life with epilepsy, and a CURE researcher who revealed his own struggles with epilepsy at a recent CURE event.

Every day, we're researching for you – and we won't stop until we find a cure. Thank you for your support, today and every day.

Beth Lewin Dean



CURE IS RESEARCHING...

BASIC MECHANISMS OF EPILEPSY

TO UNDERSTAND WHAT CAUSES EPILEPSY AND IDENTIFY WAYS TO STOP IT.

OF CURE RESEARCH FUNDS INVESTED IN BASIC SCIENCE SINCE 2011

RESEARCH SPOTLIGHT



Focal cortical dysplasias (FCDs) are a common cause of focal epilepsy, a difficult-to-treat condition that often requires surgery. CURE grantee Dr. Yu Wang and his team used a gene editing technique to develop a groundbreaking animal model of FCD, revealing that an existing therapy may be effective in treating focal epilepsy.

SUDDEN UNEXPLAINED DEATH IN EPILEPSY (SUDEP)

O PUT AN END TO ONE OF THE MOST DEVASTATING CONSEQUENCES OF EPULEPSY

20X

PEOPLE WITH EPILEPSY ARE 20X
MORE LIKELY TO DIE SUDDENLY THAN
THE GENERAL POPULATION 1

OVER \$4 MILLION

N SUDEP GRANTS AWARDED TO DATE

30+
RESEARCH PROJECTS

¹ Ficker D.M., Sudden unexplained death and injury in epilepsy, Epilepsia, 2000; 41(suppl 2):S7–12.

SLEEP AND EPILEPSY

TO UNDERSTAND THE CONNECTION BETWEEN SLEE And seizures for those living with epilepsy.

UP TO 25%

OF PATIENTS HAVE PREDOMINANTLY NOCTURNAL SEIZURES?

2017

CURE ESTABLISHES SLEEP AND EPILEPSY
AS A KEY RESEARCH PRIORITY, ATTEMPTING
TO BETTER UNDERSTAND THE RELATIONSHIP
BETWEEN SLEEP AND EPILEPSY IN THE HOPE
OF IMPROVED TREATMENT OPTIONS

RESEARCH SPOTLIGHT



CURE grantee Dr. Judy Liu and her team at Brown University are studying whether seizures are more likely to occur in certain stages of sleep, ultimately leading to a better understanding of sleep and epilepsy and potential new strategies to manage these seizures.

This research was generously funded by the BAND Foundation.

² Carreno M. and Fernandez S., Sleep-Related Epilepsy, Curr Treat Options Neurol., 2010; 18(5):23.

ACQUIRED EPILEPSY

TO HELP PREDICT, PREVENT, AND TREAT EPILEPSY AFTER TRAUMA TO THE BRAIN.

4.20

OF ALL U.S. TROOPS WHO SERVED FROM 2000 TO 2011 WERE DIAGNOSED WITH A TRAUMATIC BRAIN INJURY, MAKING THEM ESPECIALLY SUSCEPTIBLE TO DEVELOPING POST-TRAUMATIC EPILEPSY³

ESEARCH SPOTLIGHT:

Launched in 2018, CURE's Post-Traumatic Epilepsy Initiative features more than 60 research collaborators working to develop new research models and biomarkers and understand risk factors for this condition.

Learn the latest about the Initiative on page 10.

³ Centers for Disease Control and Prevention, Report to Congress on Traumatic Brain Injury in the United States: Epidemiology and Rehabilitation, National Center for Injury Prevention and Control, Division of Unintentional Injury Prevention, Atlanta, GA, 2015, https://www.cdc.gov/traumaticbraininjury/pdf/TBI_Report_to_Congress_Epi_and_Rehab-a.pdf.

Neurol., 2010; 18(5):23.

CURE IS RESEARCHING...

PEDIATRIC EPILEPSY

NEW CASES OF EPILEPSY ARE MOST COMMON IN CHILDREN, ESPECIALLY IN THE FIRST YEAR OF LIFE 4

CHILDREN 10 YEARS OF AGE OR YOUNGER ARE DIAGNOSED WITH EPILEPSY MAKING IT ONE OF THE MOST PREVALENT NEUROLOGICAL CONDITIONS IN CHILDREN



syndrome, a rare and catastrophic form of treatment-resistant epilepsy, could become a reality thanks to research from two CURE grantees in Australia. Dr. Glenn King and Dr. Steven Petrou identified a peptide in spider venom that successfully reduced seizures and mortality in nice experiencing Dravet symptoms.

A new treatment for Dravet

TREATMENT-RESISTANT EPILEPSY

DESPITE AVAILABLE MEDICATIONS


- ⁴ Hirtz D. et al., How common are the 'common' neurologic disorders?,
- ⁵ Aaberg K.M. et al., Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study, Pediatrics, 2017; 131(5).
- ⁶ Chen Z. et al., Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study, JAMA Neurol., 2018; 75(3):279-286

RESEARCH

Since its inception, CURE has been at the forefront of epilepsy research, raising over \$70 million to fund research and other programs that will lead the way to a cure for epilepsy.







FEATURED RESEARCH:

POST-TRAUMATIC EPILEPSY INITIATIVE

The changing nature of combat has made traumatic brain injury (TBI) a major health concern for service members, both during times of conflict and in daily life. Brought on by blast exposures, vehicle crashes, and other impacts to the head, TBI can increase the chance of developing post-traumatic epilepsy (PTE), a debilitating condition defined by recurrent seizures. Research from the Vietnam, Afghanistan, and Iraq wars has shown sharply increased rates of PTE in troops who sustained TBI.

Research also shows PTE represents approximately 20% of all symptomatic epilepsy cases, occurring among veterans and civilians alike. Currently, there is no way to predict or prevent PTE, and treatment options are often ineffective and can have severe side effects. With hundreds of thousands of service members diagnosed with TBI since 2000, the need for innovation in research is clear.

INSIDE THE INITIATIVE

CURE's newest signature research effort, the Post-Traumatic Epilepsy Initiative, is an ambitious multidisciplinary program that seeks answers for veterans and others affected by this condition. Funded through a \$10 million U.S. Department of Defense grant, the Initiative takes an innovative team science approach to better understand the causes of post-traumatic epilepsy, which may one day support development of new treatments. Through this work, CURE investigators aim to develop:

AND

BIOMARKERS TO IDENTIFY
SOMEONE'S RISK OF
DEVELOPING PTE FOLLOWING
A TBI


THAT LEAD TO

THERAPIES TO PREVENT OR HALT PTE



Salazar A.M. et al., Epilepsy after penetrating head injury. I. Clinical correlates: a report of the Vietnam Head Injury Study, Neurology, 1985; 35(10):1406-1414.





Pugh M.J. et al., The prevalence of epilepsy and association with traumatic brain injury in veterans of the Afghanistan and Iraq wars., J Head Trauma, 2015; 30(1):29–37.

TAKINU UN L'ASAIER

📤ss multiple institutions, h a specific focus related o TBI and PTE.

Under the oversight of CURE, the Department of Defense, and an external advisory council, the investigators exchange data, materials, and models in real time as they work toward shared goals. This approach allows the Initiative to adapt as researchers share findings, informing the program's overall direction to make the outcomes as impactful as possible. Through collaboration and shared discovery, the Initiative aims to provide results that can improve the lives of people everywhere living with post-traumatic epilepsy.



PRINCIPAL INVESTIGATOR:

Focusing on an animal model as well as humans with subarachnoid hemorrhage, a common type of bleeding following TBI, Dr. Loeb and his team are utilizing EEG and imaging to uncover potential biomarkers for PTE.

MEET THE TEAM



Using a mouse mode

TBI, Dr. Wang and his

unique chemical and

are seeking to uncover the

molecular processes that

lead to PTE following TBI,

areas and biomarkers for

developing treatments.

offering potential new focus



exploring cha brain's neuronal support system after TBI in a new animal model of PTE as well as in humans with moderate to severe TBI, with the goal of providing new insight into how PTE develops and new methods to identify high-risk patients.



UNIVERSITY OF PENNSYLVANIA PRINCIPAL INVESTIGATOR:

Using a novel animal model along with human tissue from those affected by TBI, Dr. Johnson and her team are studying the relationship between the detrimental neural changes that can follow TBI and the development of PTE.



MID-ATLANTIC EPILE AND SLEEP CENTER PRINCIPAL INVESTIGATOR:

Dr. Klein and his tear

to examine a group of at high risk for PTE, sea for biomarkers in patient signatures, MRIs, or blood can help predict who is at an increased risk of developing this condition.



In response to the need for additional animal models of PTE, Dr. Sontheimer and his team are investigating the ways TBI leads to PTE in both an established as well as a new mouse model of PTE.



THE POWER OF DATA

In partnership with the University of Southern California's Laboratory for Neuro Imaging, the Post-Traumatic Epilepsy Initiative is creating a database to store team data for cross-comparison and analysis, as well as electronic case report forms with common data elements for clinical and preclinical TBI.

The Initiative is also supporting the International League Against Epilepsy/ American Epilepsy Society Joint Translational Task Force's efforts to develop electronic case report forms containing common data elements for preclinical epilepsy research. Using common elements will help to increase rigor, transparency, and reproducibility in epilepsy research.

RESEARCHER QSA UNIVERSITY OF WASHINGTON



You've spent nearly 40 years researching epilepsy. What initially drew you to this field of study?

When I began graduate school in 1980, I knew that I wanted to study neuroscience, but I knew very little about epilepsy. However, I soon realized that epilepsy as a field of study was extremely interesting to me, because it provided a window into the complexity of the brain. At the time, the community was learning more and more about the neurobiology of epilepsy and how seizures start and spread. I realized quickly that trying to understand epilepsy at a neurobiological level was both fascinating and important work.

Like many graduate students, my career was shaped early on by my mentor, Dr. Dixon Woodbury, who was passionate about his work to advance a greater understanding of the mechanisms of action of antiseizure drugs and the role of the non-neuronal glial cell in seizure onset and progression. Dr. Woodbury was a strong advocate for his students. At every meeting we attended, he would take me and his other students under his wing and introduce us to the greater epilepsy community. The more scientists and clinicians I met, the more I began to appreciate the passion they had for their work and their patients.

You've played a role in the development of several new antiseizure drugs and served in multiple leadership roles throughout your career. What are your proudest achievements

First, I want to acknowledge that any achievements that I may have enjoyed have been possible because of the team of dedicated individuals I've been fortunate to work with over the years. Since 1993, the

Anticonvulsant Drug Development Program at the University of Utah has touched all of the new seizure drugs on the market in some way. To know that this work contributed to the clinical advancement of several new antiseizure drugs has been extremely rewarding for the entire team. On a personal note, I think a lot about how our work together over the years has contributed to a better quality of life and seizure control for people living with epilepsy. Being the beneficiary of one of the antiseizure drugs first screened by the University of Utah Program, I am reminded twice daily how modern science and drug discovery can change lives by bringing new therapies to the marketplace. In addition, the team at Utah has been able to advance new animal models for drug screening, work that has impacted how the National Institute of Neurological Disorders and Stroke's Epilepsy Therapy Screening Program evaluates new drugs. I am so pleased to see how this work continues today under the leadership of Dr. Karen Wilcox. I am also so proud of my work with CURE, particularly the Infantile Spasms and Post-Traumatic Epilepsy Initiatives. I have over the years been humbled by the support from the entire CURE family, not only for me but for all people with epilepsy and their families.

After a generalized tonic-clonic seizure in 2010, you were eventually diagnosed with focal epilepsy. How has your diagnosis impacted your personal and professional life?

In that moment, I got my first glimpse into what the lives of 60 million people living with epilepsy must be like on a daily basis. I can honestly say that there's not a day that goes by that I don't think about it, and how

it's impacted me and my family. I remember waking up in the emergency department and being told that I had had a seizure, but not to worry because "everyone gets their first seizure for free." Even though I tried to rationalize the seizure on the basis of sleep deprivation and stress, I knew enough about the disease state to know that no one gets any seizure for free and that there was likely an underlying cause that could not be so easily dismissed. If I have ever wanted to be wrong, it was that night. Unfortunately, shortly after an MRI the next morning, I found myself meeting with the Chief of Neurosurgery at the University of Utah discussing neurosurgery to remove an unidentified mass that the MRI had identified in my brain. When the pathology report suggested that my tumor was a low-grade nonmalignant brain tumor, I realized that I was very fortunate to have incredible access to the healthcare system and the best doctors and health care team at a time when I needed it. That's something I fear doesn't exist for a large percentage of people faced with a similar situation.

You were fortunate to find a treatment that has helped you control your focal seizures.

How do you continue to manage your epilepsy day to day?

Eighteen months after the neurosurgery, I started having focal events that were becoming more frequent and longer in duration. In my mind, I realized they were probably focal seizures and I had prepared myself for the diagnosis. No matter how much I had prepared myself, hearing the words "focal epilepsy" was when the full irony of the situation hit home. To think that I now have a diagnosis for a disease that I had studied my entire career, and that I was taking an antiseizure drug that was first screened by the team I directed during my tenure at the University of Utah, has certainly personalized how important science is and that we cannot stop seeking better treatments for this disease.

You publicly announced your epilepsy diagnosis at the American Epilepsy Societ (AES) conference last year. What inspired you to share this news with the community

It was a decision that took me years to make. I remember a conversation with Susan Axelrod and Dr. Dan Lowenstein a number of years earlier about how the landscape for epilepsy research might change if those of us with the disease were able to speak out and take ownership. Easier said than done, I told myself. I, like many others, felt almost paralyzed by the stigma that still exists around epilepsy. I worried about how my friends and colleagues would react. My decision to go public slowly evolved over the last two years. The last two summers, I've been fortunate to travel with a group of 20 to 25 pharmacy students to Ghana on a Global Brigades Medical Mission, where we interviewed a number of people with epilepsy and their caregivers in an effort to understand their needs and how the 85% treatment gap was affecting their

access to healthcare and medications. I wanted to share my story, thinking that in some way it might help ease their pain and anxiety, but I could not find my voice. Long story short, I finally figured out that I could no longer sit silent. I have found great solace in being able to speak openly about what life is like with epilepsy. The diagnosis no longer controls me; I control it by being open with friends, colleagues, and students and there is no longer a reason for me to hide. I've been very lucky, and I hope that my story can drive science and advocacy forward to ultimately help others.

After I shared my story at AES, I was moved by the level of support I received. People kept coming up to me to tell me that they or a child had been personally affected by epilepsy. I couldn't think of a better place to have had that conversation than with the CURE family present. I will always cherish the warmth that I felt, and I will be eternally grateful for the support that was shared with me and my wife, Kathryn, that night.

What are your hopes for the future of epilepsy research?

If I have one big hope, I don't want to be standing here 20 years from now and still not have a cure or a treatment for those patients with treatment-resistant epilepsy. My hope is that we can use the knowledge of an ever-evolving science to finally find that transformative therapy that will someday alter or prevent the development of epilepsy in the susceptible individual. To do that, we need to all be strong advocates for epilepsy research and provide assurance that it is okay to talk about epilepsy.



"Being the beneficiary of one of the antiseizure drugs first screened by the University of Utah Program, I am reminded twice daily how modern science and drug discovery can change lives by bringing new therapies to the marketplace."

DR. H. STEVE WHITE. UNIVERSITY OF WASHINGTOI

RESEARCH HIGHLIGHTS

TREATMENT-RESISTANT EPILEPSY

UNCOVERING CONNECTIONS BETWEEN GRIN GENE MUTATIONS AND EPILEPSY

THE REALITY


N-Methy-D-aspartate receptors (NMDA-R) are an essential component of electrical signaling in the brain and have recently been linked to many epilepsies. NMDA-Rs are made up of proteins encoded by the GRIN family of genes. Mutations in GRIN genes can therefore impact how NMDA-R works.

THE RESEARCH

Dr. Stephen Traynelis and his team at Emory University are looking into previously unstudied GRIN gene mutations to see which ones produce a strong overactivation of NMDA-R, making them potential candidates for off-label treatment with drugs that reduce NMDA-R function.8 The team has also created a registry where patients with GRIN mutations can sign up to determine if they are good candidates for these off-label treatments.



The team plans to evaluate how effective these treatments are for patients, providing clues into whether particular GRIN mutations may be better-suited for these treatments than others. The study is expected to provide data for a clinical trial, which could lead to new therapies for these difficult-to-treat epilepsies.









SUDEP

THE REALITY

People living with epilepsy are at higher risk of unexplained death, but the reasons largely remain a mystery. To address this devastating phenomenon, scientists are working to uncover what puts people at greater risk of Sudden Unexplained Death in Epilepsy (SUDEP).

THE RESEARCH

By analyzing the medical records of more than 250 people who died from SUDEP, Dr. Torbjörn Tomson at the Karolinska Institute in Sweden and his team recognized a common thread: generalized tonic-clonic seizures (GTCS). While GTCS was the most important risk factor, the team found that sleeping alone heightened those risks even more.9



THE RESULTS

This data confirms previous research showing that unattended generalized tonic-clonic seizures are the biggest risk factor for SUDEP. These findings suggest that improved seizure monitoring devices, sleeping with someone else in the room when possible, and treatments to reduce seizures could all be potentially lifesaving interventions for people with GTCS.

This research is generously funded by the Leisher Family Award.





WHAT ARE GRIN GENES?

The glutamate ionotropic receptor NMDA type subunit (GRIN) family of genes make proteins that form NMDA-R, an essential component of electrical signaling in the brain. Mutations in these genes can affect how the NMDA-R works, resulting in certain types of epilepsies.

Sveinsson O. et. al., Clinical risk factors in SUDEP: A nationwid 2020;94(4):e419-e429.

CONGRATULATIONS TO OUR

CURE GRANTEES

CURE EPILEPSY AWARD GRANTEES

This award reflects CURE's continued focus on scientific advances that have the potential to truly transform the lives of those affected by epilepsy.



UNIVERSITY OF WASHINGTON

Dr. Mefford and her team will explore if a process called "abnormal methylation" is a cause of severe pediatric epilepsy syndromes known as developmental and epileptic encephalopathies.



EMORY UNIVERSITY

Dr. Varvel and his team will focus on status epilepticus – a neurological emergency with a seizure lasting more than five minutes or when a person doesn't return to consciousness following multiple seizures. Building on previous findings, the team plans to test an approach to relieve the detrimental effects of these seizures.



FLOREY INSTITUTE, AUSTRALIA

Dr. Reid and his team will work to identify key SUDEP risk factors by developing new rodent models that replicate having both epilepsy and a genetic heart abnormality

TAKING FLIGHT AWARD GRANTEE® • • • • • • • • \$100.000 FOR ONE YEAR

This award seeks to promote the careers of young • • • epilepsy investigators, allowing them to develop a research focus independent of their mentors.



BIN GU. PHD UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

Dr. Gu and his team plan to use a unique resource - genetically diverse mice – to identify genes that increase susceptibility to SUDEP.

......

.



MID-ATLANTIC EPILEPSY AND SLEEP CENTER

Dr. Klein and his team plan to address the current inability to predict who will go on to develop PTE following a traumatic brain injury by examining a group of high-risk patients with a greater chance of developing PTE.



UNIVERSITY OF ILLINOIS, CHICAGO

Dr. Loeb and his team are studying subarachnoid hemorrhage, a type of bleeding that commonly occurs following a brain injury and is known to produce seizures. Their goal is to understand and predict who is at risk for developing this condition to identify potential treatment strategies.

Learn more about the Initiative on page 10.

EDUCATION



EPILEPSY EDUCATION FROM EVERY ANGLE

LEADERS IN EPILEPSY RESEARCH WEBINAR SERIES



DR. KAMIL DETYNIECKI UNIVERSITY OF MIAMI

DR. NATHAN FOUNTAIN UNIVERSITY OF VIRGINIA

When a seizure becomes an emergency, rescue medications are a critical lifeline to provide relief and prevent the need for emergency care. In this special two-part webinar, leading experts on this topic explore different types of seizure emergendies, current therapies, and promising research that could lead to new effective rescue medications.



DR. KATE DAVIS UNIVERSITY OF PENNSYLVANIA

Surgery can be life-changing for patients with uncontrolled epilepsy. As this area of epilepsy research and treatment evolves, this webinar highlights the types of surgeries currently available to patients, potential risks and benefits, and who is an appropriate candidate for surgery.

AND REGISTER FOR **OUR LIVE WEBINARS AT**



UNIVERSITY OF CALIFORNIA SAN DIEGO

JOHNS HOPKINS CHILDREN'S CENTER

Can changing your diet help control seizures? This webinar discusses dietary therapies from a research and clinical perspective, including the effectiveness of the ketogenic diet and which patients are the best capdidates for this type of treatment.

EXPLORE UPCOMING TOPICS



SEIZING LIFE®

NANCY IIDA







TACKLING LIFE WITH PTE AND CTE

A former NFL player and broadcaster, Adamle shares his 20-year fight against the effects of post-traumatic epilepsy and how he's working to give hope to others dealing with the condition.

TESTING CAN MAKE A DIFFERENCE DR. JOHN MILLICHAP, PEDIATRIC EPILEPTOLOGIST, ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO

With hundreds of epilepsy-related genes, how can you know if you or your child are a candidate for genetic testing? In this episode, Dr. Millichap discusses the basics of epilepsy genetics and the potential power of testing for patients and their families.

YOU'RE NEVER TOO YOUNG TO BE A HERO HENRY AND NANCY IIDA

After having a seizure in gym class while his classmates watched, Henry Iida knew he wanted to find a way to fight back. With his mother's help, he's raised \$50,000 for epilepsy through Henry's Heroes.

SURVIVING (AND THRIVING) IN COLLEGE WITH EPILEPSY **EVA AND MICHELLE WADZINSKI**

College is a big transition for any student – so what's it like for a student living with epilepsy? Eva and her mother, Michelle, share how she's balancing the stresses of college with her condition and strategies that can help make college easier for others with epilepsy.

KNOWING THE SIGNS OF INFANTILE SPASMS AMY BRIN MILLER, EXECUTIVE DIRECTOR, CHILD NEUROLOGY FOUNDATION

Infantile spasms is a rare and severe form of epilepsy, making swift detection essential to prevent cognitive and developmental delays. In this episode, Miller shares what parents should look for and what to do next if their child has spasms.





From our annual benefit to local block parties and fundraisers, our supporters are making a difference in the search for a cure in so many ways.





AES EPILEPSY CONFERENCE









\$2 MILLION RAISED AT OUR ANNUAL BENEFIT






































THANK YOU TO OUR CHAMPIONS

Heroes come in all sizes at CURE. Our CURE
Champions had their most successful fundraising
year ever, raising nearly \$375,000 to advance
lifesaving research for epilepsy. Large or small,
every gesture of generosity makes a big difference



WHAT DOES CURE CHAMPIONS SUPPORT?

NEARLY \$375,000 RAISED IN 2019 =

1 CURE EPILEPSY AWARD (\$250,000)

1 TAKING FLIGHT AWARD (\$100,000)




























CURE IS RESEARCHING FOR...



I will never stop advocating on [Adelaide's] behalf, raising awareness and money for research so that families in the future will receive their epilepsy or neurodegenerative diagnoses along with a treatment plan to full recovery. I promise...that I will fight for science to catch up to the next child, even though it could never catch up to her."

KELLY CERVANTES, ADELAIDE'S MOTHER

Adelaide passed away in 2019 from complications from epilepsy, days before her 4th birthday. While treatment is so helpful, ultimately it doesn't end our fear or struggle. In fact, the medicine that stopped Vera's recent seizures has been known to lead to permanent blindness. So medicine in the long run is not ideal. What we need is a cure."

ELVIN AND CINDY ANGULO, VERA'S PARENTS

1-year-old Vera has Sturge Weber Syndrome, a rare condition that causes vision issues and epilepsy. l'm one of the lucky ones because I finally found a drug that works for my epilepsy. Never finding a proper drug should not be something that happens.
Thanks to CURE's Educational Enrichment Fund scholarship, I plan to major in biological sciences and eventually to help patients as both a clinician and researcher."

CLARE TYLER

The Educational Enrichment Fund supports students so they can become agents of change in the epilepsy community. Meet all the 2019 scholars at cureepilepsy.org/ scholarships. Pat has tried several medications [for his post-traumatic epilepsy] but continues to suffer from seizures. At this point, I fear our options are running out."

PATTY HORAN, PAT'S WIFE

Pat developed post-traumatic epilepsy after being shot during a mission in Iraq in 2007. Learn more about CURE's newest research initiative on post-traumatic epilepsy on page 10. You can't let the bad times stop you from doing what you love."

MICHAEL PLATT

14-year-old Michael started cupcake company Michaels Desserts to combat hunger. After an epilepsy diagnosis prevented him from activities like gymnastics and diving, Michael discovered his passion for baking. Watch Michael share his story with David Axelrod at cureepilepsy.org/michaelsdesserts.

At CURE, we're researching every day for those living with epilepsy.

36 |

2019 DONOR LIST

We depend on your support every day.

Every day, we move one step closer to curing epilepsy and we're humbled to have you with us along the journey.

Thank you for your support.

While space permits us to only list some of our 4,500+ donors, our gratitude for every gift is limitless. Each and every donation is critical to driving epilepsy research forward toward a cure. Thank you.

Anonymous

Debra Cafaro and Terrance Livingston

Lisa and Michael Cotton Shery and David Cotton

Grosvenor Capital Management

Ann G. and James B. Ritchey Foundation

Alexandria Real Estate Equities, Inc.

Anonymous

Citadel LLC

Greenwich Biosciences

Deborah Kirshner and Paul Heldman

Ravichandran Foundation

Isaiah Stone Foundation The University of Chicago Medicine

Anonymous

Susan and David Axelrod

Douglas and Joanne Berry Charitable Fund

Crown Family Philanthropies

The Shurl and Kay Curci Foundation

Development Specialists, Inc.

Eisai Inc.

Carrie and Matthew Garman

Jerome Foundation

Cathy and Oscar Munoz

The Pritzker Traubert Foundation

Cari and Michael I. Sacks

Storment Family Fund

Sunovion

Emily Sachs Wong and Thad Wong

AKPD Message & Media

American Airlines

Anonymous (2)

Susan and Stephen Austin

Sarah and Paul Auvil

Barack Ferrazzano Kirschbaum

& Nagelberg LLP

Ellen Benninghoven and Michael Schafer

Ann and Doug Benschoter

Bergstein Family Foundation

Libby and Victor Boyce

Liane Kupferberg Carter and Marc Carter

Cisco

ComEd, An Exelon Company

Dara and John Corkery

Nancy and Sean Cotton Shalee and Blake Cunneen

David Yurman Enterprises LLC

John Del Cecato

The Driscoll Foundation

Suzanne and Albert Friedman

Jane Gannaway

Gibi ASMR

Josephine and Alexi Giannoulias

The Joseph Gomoll Foundation Inc.

Barbara Greis and Howard Gottlieb

Karen and Larry Grisolano Julia and Albert Hofeld

Celia and Daniel Huber

Irish Woods Foundation

Jenner & Block LLP

Lois and Aaron Johnson Carol Jones and Thomas Hynes

Bernadette Keller and William Daley

Kirkland & Ellis LLP

Kivvit

Burks Lapham

Debbie and Cory Lipoff

Desiree Lynch

Anthony Marino

Roxanne and Rocco Martino

Louise and Steven Mason

McKinsey and Company

Cheri and James Niewiara

Evelyn Nussenbaum and Fred Vogelstein

Cozen O'Connor

Sharon O'Keefe and Hal Moore

Stacey and John Pigott

PNC Bank

Linda and Richard Price

John Ray

Molly Reinhart

Michele Schara and Randy Mehrberg

Leonard and Lois Sharzer

Amrit and Gurpreet Singh

Patricia and Donald Taylor

The University of Chicago

Wachtell, Lipton, Rosen & Katz Alexandra Wentworth and

George Stephanopoulos

Ellen Alberding and Kelly Welsh

Ann & Robert H. Lurie Children's Hospital of Chicago

The Apple Lane Foundation

Loretta and Walter Anderson

Anonymous

Aura

Liz and Mike Axelrod **Edward Baker**

BNY Mellon Wealth Management

Kimberly Borden

Nancy Calcagnini

Kelly and Miguel Cervantes

The Chartis Group

Chicago White Sox

CNA Foundation

Dominic Collamat

Conagra Brands Credit Agricole CIB

Criteo

Anthony Crocilla and Dominick Crocilla

David Binder Research

Bill DeGironemo

Ellen and Scott Diamond

Kay and Karl Fricke

Jody and Mark Furlong

Virginia and Alan George

Catherine Gibbs

Goldman Sachs

Jennifer and John Heim Henry's Heroes Foundation Inc.

Michelle Hodges

Audrey Holder

John Huguenard

Donna Johnson

Barbara Keller

Ellie Kemper

Knopp Biosciences

Jennifer and Keith Kuells

Alex Lacamoire

Colby Lamberson Gardiner and Nick Lapham

Legacy Wealth Management Group

of Wells Fargo

Evelyn Lincourt Charitable Fund

Amy and Nils Lofgren

Daina Lyons and Forrest Claypool

Marino Chrysler Jeep Dodge

John Marlott

Doug Martin

Lauren Marx-Abel Jett McCandless

Kathleen and John McKenna

Mesirow Financial

Motorola Solutions Foundation

MUFG Union Bank Mina and Paul Naleid

Suzu and David Neithercut

Northwestern Memorial Hospital

Northwestern University Feinberg School of Medicine

The Oak Foundation USA Mary O'Brien

Kathy and Bob Dodd

Kathleen and Melvin Bedree

Sally and John Filan

Osprey Foundation	Joanna Edgell	Theresa Behrle-Mohs and Richard Mohs	Jana and Jeff Fillbach	Deborah Kiley	John Nish
Mariana and Joe Parke	Jackie and Alfred George	Cheryl Beil	Cherissa Fischer	Kiwanis Club of Orland Park	Linda Norby
PricewaterhouseCoopers LLC	Anna Giannoulias	Elizabeth Bell	Lynn Fleisher and John Roberts	Henrik Klitgaard	Michelle Obama and
Judith Pomeranz	Sam Gonzalez	Gwyneth Bent	Brenda Fleissner	Daniel Kohnen	The Honorable Barack Obama
Michael Polsky	Nicki and Matthew Huels	Lance Bigelow	Maureen Flood	Sally Koons	Kelley and Sean Owen
Emmett R. Quady Foundation	Sheela Jeevandam	Carolyn and Richard Block	Recia Frenn	Cathy Kopf	Pfizer Foundation
Julie and Robert Ramirez	Katie Kitchen and Paul Kovach	Carolyn and William Blodgett	Mary Frey and William Bennett	Francine and William Krasker	Pamela Phillips
Polly and Kenneth Rattner	Gale and Mark Kozloff	Michele Boroughf	Meghan Friend	Prema Krishnan	Brenda Pluger
Laura Ricketts and Brooke Skinner Ricketts	Donna LaPietra and Bill Kurtis	Derek Bradford	Mary Gager	Nancy and Paul Kurland	Mara and David Pohl
Jennifer and Jeffrey Robinson	Toby and Greg Lewis	Jennifer Breen	Orion Galey	Kevin Lada	Samantha Pollino
Paula Robinson-Doyle	Mary and Larry Liebscher	Lucy and Robert Bremner	Lois and Dennis Gates	Warren Lammert	Tanya Popp
Lori Rotskoff and Michael Canter	John Little	Julie and Keith Brunini	Roger Gay	Michael Leavitt	Shyam and Elizabeth Prabhakaran
Amy Rule and The Honorable Rahm Emanuel	Steve Lurie	Sally Cardamone	Stephanie Geary	Colleen and James Lee	Rebecca Anhang Price and Matthew Price
Bettylu Saltzman and Paul Saltzman	Laura and Donald MacDonald	Michael Cardozo	Gemini Gymnastics Academy	Lynne Levey	Melissa Quick
Martha Sayre	Andrea Mathews	Emily and Matthew Carr	Gerber Family Fund	Jill and John Levi	Stephanie Rea
Marjorie and Matthew Schneider	Peggy and Mike Meagher	Colin Carter	Tomas Gorny	David Lichtenheld	Lisa Reyes
Kristin and Andrew Seaborg	Caroline Moyer	Steven Casey	Jared Green	Katherine Linzer	Lauren and Edward Rimland
Richard Silveria	Members of the Nelson Family	Diego Celayeta	Brian Greenlees	leffrey Loeb	Jeannine Ringland-Zwirn and Howard Zwirn
Andrea and Marty Singer	Stefanie O'Keefe	Megan and Kim Chacon	Terri and Gary Grefer	Jacqueline Logan and Whitney Magruder	Louise Roberts
SK Life Science Inc.	Michele and Mark Patterson	Chase Chavin	Edith Gregson and Erik Smith	Mr. and Mrs. Barry Long	Elizabeth Robinson and Gordon Robinson
Andrea Lavin Solow and Alan Solow	Anna and Raymond Pitera	John Clark	Lisa Gustavson	Roberta Lowell	Kathleen and Fred Robinson
Chris Stamp	Patti and Kenneth Raskin	Michael Clark	Inna Halperin	Stephanie Lowell and Gregg Duthaler	Anne and Kyle Rockey
Steve Quick Jewelers	Loretta and Michael Robinson	Kathryn Celeste Coats	Amanda Hamo	Dan H. Lowenstein	Jennifer Roos
•	Lori Sapio	•	Deborah and James Hardin	Laura Lubbers and Trent Buck	Priscilla and Russell Rose
The Strategy Group Michael Swell	Christing and Zac Schneider	Patricia Collins and Gordon Greenberg	Deboran ana james Harain Donald Harmon		Lauren Rosen
		Denise and Vincent Comparato Sarah and William Cool	Donaia Harmon Lee Hecht Harrison	Francesca Maggi	Laura and David Ross
Margaret and Joseph Tilson	Erin Schael and David Schonthal			The Malkin Family	Barbara Rothway
Patricia and Daniel Ushman	Gene Schoon	Kate and Matthew Cooper	Michelle and John Hart	Peter Mark	Kellie and Kris Sadens
Cate and Frederick Waddell	Lisa and Randy Siegel	Kim and Rob Coretz	Patricia and Paul Hartnett	Kim and Donald Matthews	Hamed Saeed
The Walsh Foundation; Patty and Dan Walsh	Doug Smith	Jo Ann and Steven Corson	Sarah Hegeman	Sarah Matthews	St. Patrick's Episcopal Day School
Mr. Eric Weil	Hollis Stern	Laura Coulter and David Reifman	John Heilemann	Nancy Mattice	Christiane and Phillip Salvador
Reggie Whitten	Linda and Donald Stewart	Crescent Grove Advisors	John Hennegan	Garrett McCarthy	Colleen Savage
Heather and Tom Wurzer	Theater at the Center	Pam and John Cullerton	Kay Henrichs	Sophia McCarthy and Andrew Hronek	Margaret Scanlan Brown
VanTrust Real Estate, LLC	Triford Foundation	David Dahlberg	Helaine and Peter Heydemann	McClelland Family Foundation	Michelle Schaeffer
	Terrence and Laura Truax	June and Stan Dean	Amanda Hitesman	Brigid McGrath	Margaret Schell
	Barbara and Michael Urbut	Traci DeAngelis	Melissa Hoffman	Lark-Marie Menchini	Diane Scherbarth
	Bruce Wedel	Jennifer DeBower	Rabbi Lawrence Hoffman	Tom Mendel	
Ariel Investments	Cathy and John Wheeler	Matthew Decker	Christopher Hollinger	Mercedes-Benz of Des Moines	Erin Scherbinske
Sidley Austin LLP	Connie Wishner	Jamie Dennis	Terry Hong	Sandra and Andrew Merrill	Robin Schirmer and John Bouman
Autism Science Foundation	Clarkson C. Wormer	Patricia DiCianni	Abbey Horwitz	Hanne and John Messerich	Andy Schlensky
Susan and Andrew Arnold		Michael DiDonato	John Hunt	Maggie Michelson	Susan Schneider and James Schneider
SC Benjamin Foundation		Maggie and Antonio DiPaolo	Janet and David Hyland	Laura Milani	Jamie and Marty Schrero
Kathy and Jeff Berg		Alison Donalty and Chris Hampson	Rick Jasculca	Krysia and Michael Miller	Michael Schultz
James Bohnen	Michael Abrams	Jeanne and Barry Donalty	Julie Jensen	Janice and Ken Milnes	Glenn Schwartz
Jeffrey Boutilier	Jennifer Addy	Kelly Dougherty	Sheri and Mark Jessell	Janet and Mike Moore	Jack Segal
Mary Cain	American Idiot Broadway Family	Jillian Dryfoos	Edward Johnson	Kenneth Moore	Select Equity Group Foundation
CEMEX	Cindy and Elvin Angulo	Joe Dwyer	Sally and William Johnson	Stephen Moore	Rosalind and Khiang Seow
Chicago AMWA Consortium	The Arcelus Family	Katie and Ted Eberspacher	Melanie Karlberg	David Morrisey	Donna Severson
Timothy Cook	Matthew Armas	Eli's Cheesecake Company	Jessica and Glen Kaufman	Kathleen and John Morrissey	Ajay Shah
Patti Jo and James Cunneen	Linda and Jesse Averett	Patrick English	Susan and Jules Kaufman	Luis Morales	Ravishankar Shanmugam
Sara and David Decoste	Ethan Axelrod	Megan Fabian	Jackie Kazarian and Peter Cunningham	Darcy and Andrew Mouton	Tracy and Lawrence Shar
Julia and Richard Diasio	Aamer Baig	Fairgrounds Coffee	Colin Kealey	Beth and Mark Myers	Robert Shultz
Cameron Dodd	Lisa and Timothy Bazemore	Debra and Steven Fendrich	Barbara Kelly	Sara and Patrick Nash	Cassia Shumate
Kathy and Pob Dodd	Kathleen and Melvin Pedroe	Cally and Lake Eller	Callaga Managa and Chair Thanag	Constitution Admittally Attall	Circus Ivo

40 | cureepilepsy.org | 41

Colleen Kenyon and Chris Thome

Cecilia Molick Nish

Simplus

William Singer

Brian Sinotte

Roz Skozen

Michael Slovis

Charles Smith

Susan Soergel

Dana Soltani

Heidi Steiner and Daniel Weiss

Susan Steiner Sher and Neil Cohen

Candice Steller

Amy and David Stender

Paul Stovall

Carolyn Strobel

Nancy and Stephen Summers

Eileen Sutula and Thomas Sutula

Kim and Robert Swidler

Andrea and Anthony Tahlier

Priya Tatachar

Vina Taylor

Vicki Taylor-Roskopf

Bill Terlato

Alexa Tidabeck

Laura Tucker and Peter Giangreco

Mike Turner

Brian Tweedie Edred Utomi

Robert Vanecko

Claudia Wagner and Don Lebowitz

The Waldman Family Charitable Trust

Margaret and Blane Warhurst

Bruce Watrous

Barbara Weade and Michael Goc

Sanford Weinstein

Travis Wellman

West Monroe Partners

Whitaker/Ellis

Laura and Bruce White

Eleanor Wiegand

Matthew Wilcox

Jan and Daniel Willison

Mary Willoughby

Laura Wise

Linda and John Woodford

Faye Yang

John Yonover

Jamie Zeek

Judith Zwirn

CURE CHAMPIONS 2019

:26 The Art of Epilepsy - Boston

21-Day Detox

24-Hour Livestream

All-Guard Auto Al

arry's Bootcamp

Blo Blow Dry Grand Opening

Charitable Cars Donatio

Comic Book Launch

Corai's Crusaders Fundraise

Criteo Fundraisei

Dressage for a Cause

Flla's Race for a CURF

Epilepsy Stigma Awareness Event

Epilepsy: Up Close an (Chicago Salon)

Evan's Facebook Campaign

Golf Outing Fundraiser

Fundraiser for Olivi

Giri Scout Iroop Fundraiser

Gon Outling Fundraiser

Hamilcast Fundraiser

House of Blues Co

ico ordani ioi a oc

inay Mini Maratho

Lunga markha a mark Allikku ala

Jumpamon ai Ailiuae

area area Daharta III Trivia Tvar

Land Grant Brewing Celebration

Lemonade for Adelaide

Lori Sapio Photo Shoo

Molly's Birthday Fundraise

Mother's Day T-shirt Sale

Orange Theory Fundra

Purple Day Concert

Purple Ribbon Gaming Event

Race For Epileps

Raw Gamers Twitch Stre

Salesforce Concert

School Fundraise

Shutouts for Seizure

Silent Auction for a CURE

Skate for Ale

Songs of Love and Revolution

Team CURE -

Chicago Half-Marathon

Team CUPE - NYC Marath

UMES Strides for Epilepsy 5

Vera's Birthday Fundraiser

Wizard World Comic Con Chicago Womens Empowerment Symposium



EADDL 2019 photos thanks to Brian Kramer Photography
Ella's Race photos thanks to Lauren Enright Photography

